“Treatment of neovascular AMD: Artificial intelligence in real-world setting”
- Source field
- authorizedApplication.authorizedPartI.trialDetails.clinicalTrialIdentifiers.publicTitle
- Matched term
- artificial intelligence
2024-518482-99-01
Registration, authorisation of a trial application, trial start, result disclosure and marketing authorisation are different facts. The dossier claims neither clinical efficacy nor safety, deployment or causality.
CTIS record ≠ efficacy ≠ marketing authorisationTerms count only in allowlisted public CTIS fields. Sponsor, medical condition, phase or a generic software reference alone is not AI evidence.
“Treatment of neovascular AMD: Artificial intelligence in real-world setting”
A status in one country is not transferred to another. Decision dates and status histories remain separate source facts.
Decisions15 January 2025 · Authorized
Country statusAustria · Authorised
The chronicle sorts published CTIS events. i6eal observation times follow on a separate clock.
No result disclosure is published in this projection. This means neither that results do not exist nor that a deadline has been missed.
The public CTIS record remains authoritative. The i6eal files are a deterministic, bounded projection.
i6eal (2026): EU AI Studies Monitor, CTIS trial 2024-518482-99-01, data state 23 July 2026. https://i6eal.de/en/tools/ki-studienmonitor/studie/2024-518482-99-01/These tools complement the current result.